These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 39076855)

  • 21. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
    Starr JA; Pinner NA; Lisenby KM; Osmonson A
    Pharmacotherapy; 2021 Jun; 41(6):526-536. PubMed ID: 33866578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions.
    Passantino A; Rizzo C; Scrutinio D; Palazzuoli A
    Heart Fail Rev; 2023 May; 28(3):683-695. PubMed ID: 34725782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
    Williams DM; Evans M
    Diabetes Ther; 2020 Oct; 11(10):2207-2219. PubMed ID: 32852697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction.
    Brust-Sisti L; Rudawsky N; Gonzalez J; Brunetti L
    Pharmacy (Basel); 2022 Nov; 10(6):. PubMed ID: 36548322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis.
    Cardoso R; Graffunder FP; Ternes CMP; Fernandes A; Rocha AV; Fernandes G; Bhatt DL
    EClinicalMedicine; 2021 Jun; 36():100933. PubMed ID: 34308311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction.
    De Lorenzi AB; Kaplinsky E; Zambrano MR; Chaume LT; Rosas JM
    Drugs Context; 2023; 12():. PubMed ID: 36660013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
    Mentz RJ; Brunton SA; Rangaswami J
    Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure With Mildly Reduced and Preserved Ejection Fraction.
    Cheng JWM; Colucci V; Kalus JS; Spinler SA
    Ann Pharmacother; 2023 Nov; 57(11):1291-1301. PubMed ID: 36800904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.
    Coats AJS; Butler J; Tsutsui H; Doehner W; Filippatos G; Ferreira JP; Böhm M; Chopra VK; Verma S; Nordaby M; Iwata T; Nitta D; Ponikowski P; Zannad F; Packer M; Anker SD
    J Cachexia Sarcopenia Muscle; 2024 Feb; 15(1):412-424. PubMed ID: 38158636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Benefits of Sodium-Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects.
    Kubota Y; Shimizu W
    JACC Asia; 2022 Jun; 2(3):287-293. PubMed ID: 36338417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients.
    Kashiwagi A; Araki S; Maegawa H
    J Diabetes Investig; 2021 Jan; 12(1):6-20. PubMed ID: 32563214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
    Jhund PS
    Heart Fail Clin; 2022 Oct; 18(4):579-586. PubMed ID: 36216487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients.
    Tanashat M; Manasrah A; Abouzid M
    Eur J Clin Pharmacol; 2024 Jul; 80(7):951-963. PubMed ID: 38498097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
    Ji PJ; Zhang ZY; Yan Q; Cao HL; Zhao YJ; Yang B; Li J
    ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS; Correa A; Contreras JP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials.
    Ji L; Mishra M; De Geest B
    Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obesity-related heart failure with preserved ejection fraction: new treatment strategies.
    Chrysant SG; Chrysant GS
    Hosp Pract (1995); 2019 Apr; 47(2):67-72. PubMed ID: 30712418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?
    Schneider CA; Pfister R
    Herz; 2022 Oct; 47(5):395-400. PubMed ID: 36018379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction.
    Pandey AK; Bhatt DL; Pandey A; Marx N; Cosentino F; Pandey A; Verma S
    Eur Heart J; 2023 Oct; 44(37):3640-3651. PubMed ID: 37674356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.